- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01428908
Immunogenicity and Safety of A Group A, C Polysaccharide Meningococcal and Type b Haemophilus Influenzal Conjugate Vaccine in Infants and Children
A Phase III Clinical Trial the Immunogenicity and Safety Study of A Group A, C Polysaccharide Meningococcal and Type b Haemophilus Influenzal Conjugate Vaccine in Infants and Children.
Haemophilus influenzae is an important pathogen which can cause primary infection and respiratory viral infection in infants and leaded to secondary infections. The infection of haemophilus is a major cause of morbidity and mortality in infants and children. At present, the developed conjugant Hib vaccine is proved to be safe and effective. Because Hib vaccine can prevent meningitis, pneumonia, epiglottis inflammation and other serious infection caused by Hib bacteria, the WHO suggested that Hib vaccine should be included in the infant's normal immune programming.
Since the use of meningitis aureus polysaccharide vaccine, incidence of a disease in recent years is declined and maintain to the level of 0.5 per 1/100 thousand. But meningitis aureus polysaccharide vaccine with a relatively poor immune response in the infants under the age of two, and the remaining 60% with a low antibody level and a short duration.
According to the present immunization schedule, to reach the median level of antibody levels there are at least 4 doses in need. So it is meaningful to improving vaccine immunogenicity, to provide high levels of long-term protection and to reduce the number of injections.
After the phase I study which was conducted in August, 2011, the safety profile of this vaccine is proved to be acceptable. The phase III study is aimed to further evaluate the safety and the immunization of the vaccine. The objective of this study is to evaluate the safety of the group A, C polysaccharide meningococcal and type b haemophilus influenzal conjugate vaccine.
Study Overview
Status
Intervention / Treatment
Study Type
Enrollment (Actual)
Phase
- Phase 3
Contacts and Locations
Study Locations
-
-
Jiangsu
-
Funing county, Jiangsu, China, 224400
- Funing County Center for Disease Control and Prevention
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
For the children (aged from 2 to 5 years old)
Inclusion Criteria:
- Healthy subjects aged from 2 to 5 years old of normal intelligence.
- The subjects' guardians are able to understand and sign the informed consent.
- Subjects established as healthy after medical history questioning, physical examination and clinical decision and in accordance with vaccination requirements of the investigational vaccine.
- Subjects who can comply with the requirements of the clinical trial program according to the researcher's views.
- Subjects who have never received group A, C polysaccharide meningococcal vaccine and type b haemophilus Influenzal vaccine.
- Subjects with temperature <37°C on axillary setting.
Exclusion Criteria:
- Subject who has a medical history of Meningitis;
- Subject that has a medical history of any of the following: allergies, seizures, epilepsy, encephalopathy history and so on;
- Subject who is allergic with tetanus toxoid components;
- Subject suffering from thrombocytopenia or other coagulation disorder may lead to contraindication to intramuscular injection;
- Subject who has a history of allergic reactions;
- Any known immunological dysfunction;
- Had received gamma globulin or immune globulin, in the past two weeks
- Subject suffering from congenital malformations, dysgenopathy or serious chronic disease;
- Any acute infections
- Any condition that in the opinion of the investigator, may interfere with the evaluation of study objectives
For the infants (aged from 6 to 23 months old)
Inclusion Criteria:
- Healthy subjects aged from 6 months to 23 months old of normal intelligence.
- The subjects' guardians are able to understand and sign the informed consent.
- Subjects established as healthy after medical history questioning, physical examination and clinical decision and in accordance with vaccination requirements of the investigational vaccine.
- Subjects who can comply with the requirements of the clinical trial program according to the researcher's views.
- Subjects who have never received group A, C polysaccharide meningococcal vaccine and type b haemophilus Influenzal vaccine.
- Subjects with temperature<37°C on axillary setting.
Exclusion Criteria for the first vaccination:
- Subject who has a medical history of Meningitis;
- Subject that has a medical history of any of the following: allergies, seizures, epilepsy, encephalopathy history and so on;
- Subject who is allergic with tetanus toxoid components;
- Subject suffering from thrombocytopenia or other coagulation disorder may lead to contraindication to intramuscular injection;
- Subject who has a history of allergic reactions;
- Any known immunological dysfunction;
- Had received gamma globulin or immune globulin, in the past two weeks
- Subject suffering from congenital malformations, dysgenopathy or serious chronic disease;
- Any acute infections
- Any condition that in the opinion of the investigator, may interfere with the evaluation of study objectives
Exclusion Criteria for the second vaccination:
- Had any Grade 3 or Grade 4 adverse reactions or events occurred since the first vaccination
- Any situation meets the exclusion criteria stated in the exclusion criteria for first dose;
- Any condition the investigator believed may affect the evaluation of the vaccine.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Triple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: children group A
600 children aged 2-5 years old, will be vaccinated on day0
|
The group A, C polysaccharide meningococcal and type b haemophilus influenzal conjugate vaccine (Wuxi Royal Biological Co., LTD, 20110101) will be administered intramuscularly on one arm, per 0.5ml dose
Placebo will be administered intramuscularly on the other arm, per 0.5ml dose
|
Experimental: infants group A
600 infants aged 6-23 months old, will be vaccinated on day0, 28
|
The group A, C polysaccharide meningococcal and type b haemophilus influenzal conjugate vaccine (Wuxi Royal Biological Co., LTD, 20110101) will be administered intramuscularly on one arm, per 0.5ml dose
Placebo will be administered intramuscularly on the other arm, per 0.5ml dose
|
Active Comparator: children group B
600 children aged 2-5 years old, will be vaccinated on day0
|
The group A, C polysaccharide meningococcal vaccine (Wuxi Royal Biological Co., LTD, 20101202) will be administered intramuscularly on one arm, per 0.5ml dose
The type b haemophilus influenzal vaccine (Sanofi Pasteur Limited) will be administered intramuscularly on the other arm, per 0.5ml dose
|
Active Comparator: infants group B
600 infants aged 6-23 months old, will be vaccinated on day0, 28
|
The group A, C polysaccharide meningococcal vaccine (Wuxi Royal Biological Co., LTD, 20101202) will be administered intramuscularly on one arm, per 0.5ml dose
The type b haemophilus influenzal vaccine (Sanofi Pasteur Limited) will be administered intramuscularly on the other arm, per 0.5ml dose
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
The seroconversion rate of antibody against group A, C polysaccharide meningitis in children after vaccination
Time Frame: 4 weeks (28±3 days) after the vaccination
|
to evaluate the seroconversion rate of antibody against group A, C polysaccharide meningitis in children when measured 4 weeks (28±3 days) after the vaccination
|
4 weeks (28±3 days) after the vaccination
|
The seroconversion rate of antibody against group A, C polysaccharide meningitis in infants after infant series
Time Frame: 4 weeks (28±3 days) after the infant series (two times, 28 day apart)
|
to evaluate the seroconversion rate of antibody against group A, C polysaccharide meningitis in infants when measured 4 weeks (28±3 days) after the infant series (two times, 28 day apart).
|
4 weeks (28±3 days) after the infant series (two times, 28 day apart)
|
The seroconversion rate of antibody against type b haemophilus influenza in children after the vaccination
Time Frame: 4 weeks (28±3 days) after the vaccination
|
to evaluate the seroconversion rate of antibody against type b haemophilus Influenza in children when measured 4 weeks (28±3 days) after the vaccination
|
4 weeks (28±3 days) after the vaccination
|
The seroconversion rate of antibody against type b haemophilus influenza in infants after infant series
Time Frame: 4 weeks (28±3 days) after the infant series (two times, 28 day apart)
|
to evaluate the seroconversion rate of antibody against type b haemophilus Influenza in infants when measured 4 weeks (28±3 days) after the infant series (two times, 28 day apart)
|
4 weeks (28±3 days) after the infant series (two times, 28 day apart)
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Injection-site reactions and systemic events after the vaccination in children
Time Frame: 7 days after the vaccination
|
to evaluate the injection-site reactions and systemic events of the investigational vaccines in healthy children for 7 days after the vaccination
|
7 days after the vaccination
|
Injection-site reactions and systemic events after the first vaccination in infants
Time Frame: 7 days after the first vaccination
|
to evaluate the injection-site reactions and systemic events of the investigational vaccines in healthy infants for 7 days after the first vaccination
|
7 days after the first vaccination
|
Injection-site reactions and systemic events after the second vaccination in infants
Time Frame: 7 days after the second vaccination
|
to evaluate the injection-site reactions and systemic events of the investigational vaccines in healthy infants for 7 days after the second vaccination
|
7 days after the second vaccination
|
GMT of antibody against group A, C polysaccharide meningitis in children after the vaccination
Time Frame: 4 weeks (28±3 days) after the vaccination
|
to evaluate the GMT of antibody against group A, C polysaccharide meningitis in children 4 weeks (28±3 days) after the vaccination
|
4 weeks (28±3 days) after the vaccination
|
GMT of antibody against group A, C polysaccharide meningitis in infants after the infant series
Time Frame: 4 weeks (28±3 days) after the infant series (two times, 28 day apart)
|
to evaluate the GMT of antibody against group A, C polysaccharide meningitis in infants 4 weeks (28±3 days) after the infant series (two times, 28 day apart)
|
4 weeks (28±3 days) after the infant series (two times, 28 day apart)
|
GMT of antibody against type b haemophilus Influenza in serum in children after the vaccination
Time Frame: 4 weeks (28±3 days) after the vaccination
|
to evaluate the GMT of antibody against type b haemophilus Influenza in children 4 weeks (28±3 days) after the vaccination
|
4 weeks (28±3 days) after the vaccination
|
Collaborators and Investigators
Collaborators
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- JSVCT007
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Group A, C Polysaccharide Meningitis
-
Prof. Elizabeth MillerNovartis VaccinesCompletedMeningococcal Meningitis, Serogroup A | Meningococcal Meningitis, Serogroup B | Meningococcal Meningitis, Serogroup C | Meningococcal Meningitis, Serogroup Y | Meningococcal Meningitis, Serogroup WUnited Kingdom
-
Noordwest ZiekenhuisgroepKarolinska Institutet; Medical University of Graz; Fondazione Policlinico Universitario... and other collaboratorsRecruitingInvasive Group A Beta-Haemolytic Streptococcal DiseaseNetherlands
-
Tampere University HospitalTurku University Hospital; University of TurkuActive, not recruitingInvasive Group A Beta-Haemolytic Streptococcal DiseaseFinland
-
Rambam Health Care CampusUnknownGroup A- 23 Implant Using Switch Platform -SPK Abutment. | Group B- 22 Implant Using the Traditional -CPK Abutment.Israel
-
Assistance Publique - Hôpitaux de ParisCompletedNeonatal Infections Colonize With Group B StreptococciFrance
-
Cairo UniversityUnknownTeeth Size in a Group of Egyptian ChildrenEgypt
-
National Institute of Allergy and Infectious Diseases...Completed
-
The Immunobiological Technology Institute (Bio-Manguinhos)...UnknownSerogroup C Meningococcal MeningitisBrazil
-
The Immunobiological Technology Institute (Bio-Manguinhos)...CompletedMeningitis, Meningococcal, Serogroup CBrazil
Clinical Trials on A+C+hib Conjugate Vaccine
-
Jiangsu Province Centers for Disease Control and...Royal (Wuxi) Biological Co., LTDCompletedInfluenza | MeningitisChina
-
Beijing Minhai Biotechnology Co., LtdCompleted
-
GlaxoSmithKlineCompletedHepatitis B | Tetanus | Diphtheria | Acellular Pertussis | Poliomyelitis | Streptococcus Pneumoniae VaccinesSpain, Germany, Poland
-
Beijing Zhifei Lvzhu Biopharmaceutical Co., LtdAir Force Military Medical University, China; Guizhou Center for Disease Control... and other collaboratorsUnknownMeningitis | Meningococcal Infections | Meningococcal MeningitisChina
-
University of OxfordUniversity College, London; Public Health EnglandCompleted
-
Jiangsu Province Centers for Disease Control and...Chengdu Olymvax Biopharmaceuticals Inc.CompletedHaemophilus Influenza
-
Sanofi Pasteur, a Sanofi CompanyCompletedHealthy Volunteers (Meningococcal Infection)India, South Africa
-
Public Health EnglandCompletedHaemophilus Influenzae Type b
-
GlaxoSmithKlineCompletedInfections, StreptococcalArgentina, Panama, Colombia
-
GlaxoSmithKlineCompletedHepatitis B | Tetanus | Diphtheria | Haemophilus Influenzae Type b | Whole Cell PertussisPhilippines